CClinicalTrials.gg
Status unknownNCT03287570Updated Oct 19, 2017

Efficacy and Safety of Cettum for Knee Osteoarthritis

An interventional study of Cettum and Traditional indirect moxibustion in Osteoarthritis, Knee, sponsored by Eun Jung Kim. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-10-19.

Sponsored by Eun Jung Kim · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is verify the efficacy and safety of Cettum (Electric moxibustion) for patients with knee osteoarthritis.

Read the detailed description

The investigator targets the patients with knee osteoarthritis. After treatment in 3 groups - Cettum treatment, traditional indirect moxibustion treatment, and usual care groups - the investigators will compare the effects of pain relieving and daily performing improvement. So the investigators will confirm the efficacy of Cettum, and further the best treatment method. In addition, the investigators are going to evaluate the safety of abnormal reaction during the treatment.

02

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Osteoarthritis, Knee
  • Moxibustion
03

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. At least 40 years of age, but below 70 years of age
  2. Presence of knee osteoarthritis diagnosed according to American College of Rheumatology classification criteria and satisfying the following 2 conditions

    • Knee pain when weight load in one or both knees in the last 6 months

      • Knee pain rated >4cm on a 10cm Visual Analog Scale (VAS)
  3. Feeling temperature sense to distinguish temperature differences
  4. An understanding of the objectives and methods of the clinical trial, and willingness in completing the consent form
  5. Those who are reliable and willing to cooperate in this test, and obey the restrictions for the next 3 months

Exclusion criteria

Exclusion Criteria:

  1. Trauma to the knee(s) within 6 months prior to enrollment, causing pain or functional problems
  2. Surgery on the knee(s) within 6 months prior to enrollment, causing pain or functional problems
  3. A history of intra-articular injection within the last 3 months
  4. A physical or laboratory finding indicating presence of an inflammatory arthritis (e.g. rheumatoid arthritis, autoimmune disease)
  5. Presence of physical or psychiatric disorder that may affect moxibustion treatment
  6. Presence of neurological disorder including paralysis symptoms on local or general sensation
  7. A female who is pregnant or is lactating
  8. Being afraid of moxibustion treatment or expected to cause side effects
  9. When researchers evaluate that it is not appropriate to participate in this clinical test
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Cettum (Electric moxibustion)

    The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.

    Device: Cettum

  • Active comparator
    Traditional indirect moxibustion

    The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.

    Procedure: Traditional indirect moxibustion

  • Other
    Usual care

    The patients in this group maintain the usual treatment and self-care.

    Other: Usual care

Interventions

  • DeviceCettum

    The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.

    Also known as: Electric moxibustion

  • ProcedureTraditional indirect moxibustion

    The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.

  • OtherUsual care

    The patients in this group maintain the usual treatment and self-care.

05

What researchers measure

Primary outcomes

  1. Pain NRS (Numeric Rating Scale) change

    The Numeric Rating Scale is a unidimensional measure of pain intensity. The 11-point numeric scale ranges from '0' representing 'no pain' to '10' representing 'worst pain imaginable'.

    Time frame: 6 weeks

Secondary outcomes

  1. 100mm Pain VAS (Visual Analogue Scale)

    The patient is asked to indicate their perceived pain intensity along a 100mm horizontal line, where '0' represents 'no pain' and '100', 'unbearable pain'.

    Time frame: 6 weeks

  2. WOMAC (Western Ontario and McMaster Universities) total

    WOMAC scale is widely used to evaluate the condition of patients with osteoarthritis of the knee, including pain, stiffness, and physical functioning of the joints. The WOMAC scale measures 5 items for pain, 2 for stiffness, and 17 for functional limitation.

    Time frame: 6 weeks

  3. EQ-5D-5L (EuroQol 5-Dimensions 5-Levels)

    The EQ-5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    Time frame: 6 weeks

  4. PGA (Patient Global Assessment)

    The patient may choose to answer the question of how much better the symptom has improved compared to the previous treatment: Very good, Good, Fair, Poor, Very poor.

    Time frame: 6 weeks

  5. Temperature sense threshold

    Investigator attaches the temperature sensor to the measurement area and increase or decrease the temperature by starting with reference temperature. Warm pain threshold and heat pain threshold are recorded to compare the difference between the value at baseline and the value at the end of the treatment.

    Time frame: 6 weeks

  6. Adverse Events

    Any unpredicted symptoms are checked at each visit and if any, the symptom, time of occurrence, and length of duration are recorded and reported.

    Time frame: 6 weeks

06

Study locations

2 sites
  • Dongguk University Ilsan Oriental Hospital
    Goyang-si, Gyeonggi-do 10326, Korea, Republic of
  • Dongguk University Bundang Oriental Hospital
    Seongnam-si, Gyeonggi-do 13601, Korea, Republic of
07

References and documents

Publications

  • Kang HR, Jung CY, Lee SD, Kim KH, Kim KS, Kim EJ. Efficacy and safety of electrical moxibustion for knee osteoarthritis: study protocol for a randomized controlled trial. Trials. 2018 Mar 5;19(1):159. doi: 10.1186/s13063-018-2514-x. PubMed 29506572 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03287570
Lead sponsor
Eun Jung Kim
Collaborators
DongGuk University
Responsible party
Eun Jung Kim (Principle Investigator, DongGuk University) — Sponsor-investigator
First posted
Sep 19, 2017
Start date
Sep 20, 2017
Primary completion
Aug 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Oct 19, 2017

Study contacts

Eun Jung Kim, Ph. D.
principal investigator · DongGuk University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion